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Context: Metformin treatment of women with polycystic ovary syn-
drome (PCOS) is widespread, as determined by studies with diverse
patient populations. No comparative examination of weight changes
or metabolite responses to different doses has been reported.
Objective: The aim of this study was to determine whether different
doses of metformin (1500 or 2550 mg/ d) would have different effects
on body weight, circulating hormones, markers of inflammation, and
lipid profiles.
Design: The study included prospective cohorts randomized to two
doses of metformin.
Setting: The study was performed at a university teaching hospital
with patients from gynecology/endocrinology clinics.
Patients: The patients studied were obese (body mass index, 30 to
37 kg/m2; n  42) and morbidly obese (body mass index, 37 kg/m2;
n  41) women with PCOS.
Intervention: Patients were randomized to two doses of metformin,
and parameters were assessed after 4 and 8 months.
Main Outcome Measures: The main outcome measures were
changes in body mass, circulating hormones, markers of inflamma-
tion, and lipid profiles.
Results: Intention to treat analyses showed significant weight loss in
both dose groups. Only the obese subgroup showed a dose relationship
(1.5 and 3.6 kg in 1500- and 2550-mg groups, respectively; P  0.04).
The morbidly obese group showed similar reductions (3.9 and 3.8 kg)
in both groups. Suppression of androstenedione was significant with
both metformin doses, but there was no clear dose relationship. Gen-
erally, beneficial changes in lipid profiles were not related to dose.
Conclusion: Weight loss is a feature of protracted metformin therapy
in obese women with PCOS, with greater weight reduction potentially
achievable with higher doses. Additional studies are required to de-
termine whether other aspects of the disorder may benefit from the
higher dose of metformin. (J Clin Endocrinol Metab 90:
4593–4598, 2005)
AFTER THE FIRST publications reporting the treatmentof women with polycystic ovary syndrome (PCOS)
with oral antihyperglycemic medications (1–4), there was an
enthusiastic subsequent exploration of effects. Recent objec-
tive reviews (5, 6) determined that the effects of metformin
on ovarian activity were beneficial, and that a number of
other potential benefits were observable in appropriately
controlled studies. These include improvements in lipid pro-
files and reductions in the circulating concentrations of an-
drostenedione, if not always testosterone. However, in the
Cochrane database review (6), despite a number of reports
observing weight loss during treatment, the meta-analysis of
current studies did not confirm that weight loss was a sig-
nificant factor. This contrasts with the comprehensive data
provided by the use of metformin in patients with glucose
intolerance in the Diabetes Prevention Program (7), in whom
significant and prolonged weight loss was recorded. Fur-
thermore, there had been debate over whether some of the
apparent improvement in ovarian function associated with
metformin treatment, such as circulating androgen and lipid
profiles, may be directly related to changes in body consti-
tution (2).
One placebo-controlled trial of metformin in women with
PCOS (8) observed that the biochemical effects and reduc-
tions in body mass were more consistent in the lean and
obese (Ob) patients than in the morbidly obese (Mob) group
[body mass index (BMI), 37 kg/m2]. This paper suggested
that such (Mob) cases are either refractory to the effects of
metformin, or they may require increased doses. One recent
study (9) also substantiated the view that obesity may reduce
the benefit of metformin treatment. Many of the studies with
metformin in women with PCOS have included large pro-
portions of Ob and Mob women, and this may be a con-
founding feature in the conclusion of the Cochrane database
review (6). Furthermore, the relationships between met-
formin and dose, and weight changes, endocrine changes,
and cardiovascular risk factors such as lipid profiles (10) and
C-reactive protein (CRP) (11) have only been sparsely
examined.
The aim of this study was to examine the efficacy of met-
formin at two different doses (1500 and 2550 mg/d) in Ob
and Mob women. The primary end point was weight loss,
with the secondary intent to examine the effects of treatment
or weight loss on cardiovascular risk factors, because these
latter measures may be an important part of the case for
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Women with PCOS (n  83), whose primary complaint was obesity,
were recruited from the Reproductive Endocrinology/Assisted Con-
ception Clinic at the Royal Infirmary (Glasgow, UK) and surrounding
hospitals. The diagnosis of PCOS included at least two of the three
features: oligomenorrhea (fewer than eight cycles per year)/amenorrhea
(fewer than two cycles per year), polycystic ovaries determined by
ultrasonography using the criteria of Adams et al. (12), or an elevated free
androgen index. Exclusion criteria included contraindications to met-
formin or its use within the previous 4 months or oral contraceptive use
within the previous 2 months. None of the women had thyroid dys-
function, hyperprolactinemia, diabetes mellitus, or late-onset or con-
genital adrenal hyperplasia. Women taking medication known to affect
weight loss, gonadal or adrenal function, or carbohydrate or lipid me-
tabolism were also excluded. Women were advised to use barrier con-
traception and were excluded if interest was expressed in immediate
pregnancy.
Written informed consent was obtained from each woman, and the
study was conducted at the Royal Infirmary after receiving approval
from the ethics committee of the North Glasgow Hospitals University
National Health Service Trust.
Study design
The study was prospective, with dose-block randomization in two
groups of patients with PCOS, defined as Ob (BMI, 30 and 37 kg/m2)
and Mob (BMI, 37 kg/m2). The patient number treatment codes were
held by a third party and were allocated after obtaining individual
written consent. Metformin (Glucophage, Merck & Co., West Drayton,
UK) doses were 500 and 850 mg, three times daily. Patients were not
blinded to treatment dose. Study assessments were performed before
treatment (T0) and after 4 months (T4) and 8 months (T8) of treatment
and included anthropometric measurements (weight, BMI, and waist/
hip ratio), ovarian structure, circulating hormones, and fasting glucose.
All patients were given the same advice concerning the benefits of
lifestyle modification through diet and exercise. No additional advice or
framework to assist weight reduction was given.
Although the study design would have been improved by inclusion
of a placebo group, it was considered that the 8-month course of treat-
ment was too excessive in the circumstances of these patients.
Assessment program
At T0, T4 (after 4 months), and T8 (after 8 months), all patients
underwent clinical and hormonal assessments. These included anthro-
pometric measurements of height, weight (BMI), and waist/hip ratio as
well as measurements of blood pressure, menstrual cyclicity, and hir-
sutism using the modified Ferriman-Gallwey score (13). Ultrasound
assessments [all performed by the same observer (L.H.)] were also per-
formed at 0-, 4-, and 8-month intervals to assess ovarian morphology and
follicular growth (ovarian volume, numbers of follicles with diameter
10 mm, and diameter of the largest follicle).
Circulating blood samples taken at each assessment point were an-
alyzed for fasting insulin, glucose, LH, FSH, estradiol, testosterone,
SHBG, free androgen index, dehydroepiandrosterone sulfate (DHEAS),
androstenedione, 17-hydroxyprogesterone, high sensitivity CRP, total
cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL-C),
high-density lipoprotein cholesterol (HDL-C), leptin, IGF-I, and IGF-
binding protein-3. Liver function, basic blood biochemistry, and thyroid
function tests were also performed.
Although there was no specific diet or exercise regimen advice given
as part of this trial, patients were asked to complete an exercise and
dietary questionnaire at each time interval (T0, T4, and T8). A side-effect
profile was also performed at 1 and 2 months.
Techniques
BMI was calculated using the equation: weight (kilograms)/height2
(meters). Waist and hip circumferences were measured to the nearest
centimeter with a soft tape according to World Health Organization
criteria. Waist circumference was obtained as the minimum value be-
tween the iliac crest and the lateral costal margin, whereas hip circum-
ference was determined as the maximum value over the gluteal region.
Ultrasound was performed by the transvaginal method using a vaginal
probe (Sonoline Sienna Ultrasound Imaging System, Transducer
6.5EV13; 6.5 MHz; Siemens, Erlangen, Germany). In each ovary, ovar-
ian volume, greatest number of follicles in any one ovarian plane, and
the diameter of the largest follicle were calculated.
Hormone concentrations were assayed in patient-specific batches to
eliminate the effect of interassay drift. Testosterone and androstenedi-
one were assessed using the semiautomated Immulite technology (Di-
agnostic Products Corp., Los Angeles, CA), and SHBG, DHEAS, IGF-I,
and IGF-binding protein-3 were assessed by the Immulite 2000 analyzer
(Diagnostic Products Corp.). 17-Hydroxyprogesterone was assayed
using an in-house RIA (intraassay coefficient of variation, 12%).
Plasma glucose was measured using the glucose oxidase method
(Bayer Advia 1650 Chemistry System, Bayer, Pittsburgh, PA), and in-
sulin was measured using a competitive RIA (Coat-A-Count I, Diag-
nostic Products Corp.). Homeostasis model assessment of insulin resis-
tance (HOMA-IR) was calculated from the fasting concentrations of
insulin and glucose using the following formula: HOMA-IR  fasting
serum insulin (microunits per milliliter)  fasting plasma glucose (mil-
limoles per liter)/22.5.
Plasma total cholesterol, triglyceride, HDL-C, and LDL-C measure-
ments were performed by a modification of the standard Lipid Research
Clinics protocol (14). Serum leptin concentrations were measured by a
validated in-house RIA (15). The intra- and interassay coefficients of
variation were less than 7% and less than 10%, respectively, over the
sample concentration range. The detection limit of the assay was 0.5
ng/ml.
Statistics
Where distributions were normal, group statistical evaluations were
compared using unpaired t tests, with Welch correction for unequal
variances where necessary, and when distributions were non-Gaussian,
the Mann-Whitney U test was applied. Changes in variables during
treatment within groups were evaluated, on an intention to treat basis,
using repeated measures ANOVA on values before treatment (T0) and
after 4 and 8 months of treatment. Absent values were substituted with
the most recent value per patient. Linear correlation examinations were
effected (in patients with completed data only) to examine relationships
between changes in weight and insulin metabolism and other param-
eters. Statistical analyses were performed using PRISM software Graph-
Pad, San Diego, CA).
Results
Patients
The randomization of the 83 patients entering the study
into the four treatment groupings produced an equal distri-
bution of 21 patients in the Ob1500, Ob2550, and Mob2550,
with 20 cases in the Mob1500 group. Within each BMI cat-
egory, there was no difference between the dose subgroups
for any parameter examined, whereas the differences be-
tween the Ob and Mob subgroups before treatment were in
line with expected values. Specifically, the Mob group
showed higher values for fasting insulin (P  0.025), CRP
(P  0.01), leptin (P  0.001), triglycerides (P  0.001), and
LDL-C (P  0.021) and lower values for glucose/insulin ratio
(P  0.003), IGF-I (P  0.002), and HDL-C (P  0.001). The
increase in the HOMA-IR evaluation in the Mob group was
not statistically significant (P  0.063).
Sixty-eight patients (82%) completed the course to the final
8 month assessment point. There was no difference in the
proportions of patients completing the study in each group
(Ob500, 18 of 21; Ob850, 17 of 21; Mob500, 18 of 20; Mob850,
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15 of 21). The main reason for discontinuation was excessive
gastrointestinal irritation.
Weight reduction and metformin treatment
Analyses of the changes in body mass in all patients re-
ceiving the 8-month metformin treatment (n  83; intention
to treat analysis) revealed that there was a highly significant
reduction (3.8%) from a mean BMI of 37.2 kg/m2, with 95%
confidence limits of 35.9–38.5 at the start (T0) to a mean BMI
of 36.1 (95% confidence limits, 34.7, 37.4) at T8 (by repeated
measures ANOVA, P  0.0001).
Dose of metformin. Table 1 examines the weight changes in the
groups treated with different doses of metformin, and it
reveals that both treatment doses were associated with sig-
nificant weight reductions over the 8-month assessment pe-
riod. At 8 months, the 1500-mg group showed a mean re-
duction of 2.5 kg (mean BMI, 36.8–37.9 kg/m2), whereas the
2550-mg group lost a mean of 3.7 kg (mean BMI, 34.5–36.3
kg/m2). The absolute weight lost did not differ between the
dose groups (P  0.35). The high dose of metformin showed
a more consistent effect on weight loss, as evidenced by the
degree of significance (by ANOVA, repeated measures), but
there was no other statistical support for this concept.
Influence of the degree of obesity. Table 1 also shows that the Ob
group treated with 1500 mg underwent no effective weight
loss, whereas all other subgroups demonstrated significant
weight reductions. Correspondingly, the Ob group showed
a metformin dose effect with respect to weight loss, because
the absolute weight lost was significantly different between
the dose groups (0  0.04). However, this was not mirrored
in the Mob group, which showed similar weight losses in
both dose groups.
Figure 1 shows that, with the exception of the Ob group
treated with 1500 mg metformin, there was a general decline
in weight of approximately 4% over the 8 months of
treatment.
Effects of metformin treatment and/or weight change
Menstrual frequency. There was effectively a doubling of the
frequency of menses during metformin treatment in those
patients with oligomenorrhea in both dosage groups. In the
1500-mg group, the mean frequency increased from 3.8 to 6.7
menses/yr (P  0.0001, by paired t test), and in the 2550-mg
group, the increase was from a mean of 3.8 to 6.8 menses/yr
(P  0.0001).
There was no apparent difference between either the dose
or obesity subgroups in the menstrual response to treatment.
The proportion of patients with oligomenorrhea who
achieved normal menstrual rhythm (10 menstrual cycles/
yr) during treatment was 36% in the 1500-mg group and 48%
in the 2550-mg group (P  0.41). There was also no difference
between the Ob and Mob groups in the proportion attaining
normal menstrual rhythm.
Blood analytes and metformin dose
Insulin metabolism. Markers of insulin resistance (fasting in-
sulin, glucose/insulin ratio, and logHOMA-IR) revealed mod-
est improvements associated with treatment in the high dose
group only (Table 2). Although there were significant
changes in the glucose/insulin ratio and HOMA-IR in the
2550-mg dose group that were not observed in the 1500-mg
dose group, absolute values at 8 months did not differ sig-
nificantly between the two dose groups (by unpaired t tests:
fasting insulin, P  0.29; glucose/insulin ratio, P  0.47;
HOMA-IR, P  0.15).
Reproductive metabolites. Table 2 also shows that circulating
androstenedione underwent a marked reduction in patients
treated with 2550 mg metformin (mean reduction, 2.5 ng/
ml), whereas the decline appeared less in the group treated
with 1500 mg (1.8 ng/ml). However, neither the concentra-
tion declines (P  0.29) nor the absolute values at 8 months
(P  0.81) differed significantly between the two dose
groups. Neither circulating testosterone nor SHBG showed
changes, and correspondingly, the free androgen index was
TABLE 1. Mean weights of all patients (all cases) and Ob and Mob subgroups treated with metformin at doses of 1500 or 2550 mg/d
n Dose (mg/d) T0 (kg) T4 (kg) T8 (kg) P (ANOVA) Weight lost (kg)
All cases (95% CL) 42 1500 104.3 (98.2–110.5) 102.7 (96.6–108.8) 101.9 (95.6–108.1) 0.0024 2.5a
41 2550 96.4 (92.1–100.7) 94.2 (89.8–98.6) 92.7 (88.2–97.3) 0.0001 3.7a
Ob group (95% CL) 21 1500 92.0 (86.2–97.8) 91.3 (85.4–97.3) 90.9 (84.3–97.6) 0.236 1.5b
21 2550 85.2 (82.1–88.2) 83.0 (79.6–86.4) 81.6 (77.8–85.4) 0.0001 3.6b
Mob group (95% CL) 20 1500 117.3 (109.4–125.1) 114.7 (106.5–122.8) 113.4 (104.8–121.9) 0.010 3.9c
21 2550 107.1 (103.0–111.1) 104.8 (100.4–109.2) 103.3 (98.7–108.0) 0.007 3.8c
Changes were evaluated using ANOVA; P values are shown. CL, Confidence limits. Unpaired t test (Welsh correction for unequal variances)
significance is indicated in abc.
a P  0.35.
b P  0.04.
c P  0.94.
FIG. 1. Decline in weight (percentage) of the metformin treatment
groups over 8 months according to obesity category and daily met-
formin dose.
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unaffected by either treatment dose. The increase in DHEAS
recorded in the 1500-mg group was not replicated in the
2550-mg group, and there was no difference between the
groups in the final concentration of DHEAS at T8 (P  0.37).
The highly significant decline in leptin concentrations in
both groups also showed no significant difference between
the treatment groups.
The circulating concentrations of LH showed no indication
of a change in either treatment group. This was despite the
changes in ovarian activity evidenced by menstrual fre-
quency noted above. Analysis of the LH values in those cases
undergoing the change from oligomenorrhea (fewer than
nine menses per year) to normal menstrual rhythm (more
than nine menses per year) revealed that these individuals
(n  21) showed modest reduction in circulating LH (P 
0.042, by paired t test) with absolute values at T0 (12.2 IU/
liter) decreasing from 11.4 IU/liter at 4 months to 7.6 IU/liter
at 8 months. This latter value would be considered to rep-
resent the high-normal range.
Lipid profiles and inflammatory markers. Table 2 also shows the
changes in lipid and inflammatory marker profiles observed
during treatment with the two doses of metformin. Signifi-
cant reductions in total cholesterol and LDL-C were observed
in both dosage groups, with no apparent dose effect. There
was no effect of either treatment dose on circulating triglyc-
erides or HDL. The highly significant reductions in leptin in
both groups were not reflected by changes in circulating
CRP, which showed no change in either dose group.
Roles of changes in weight and insulin metabolism
Changes in variables were examined with respect to
weight change and the glucose/insulin ratio over the
8-month treatment period regardless of obesity category and
dose of metformin. It is not surprising that the weight lost
(kilograms) correlated strongly with the change in the glu-
cose/insulin ratio (r2  0.16; P  0.0008). However, Table 3
shows that the changes in androstenedione were signifi-
cantly correlated only to changes in the glucose/insulin ratio,
whereas changes in circulating leptin correlated strongly (r2
 0.37) with the changes in weight and less strongly with the
glucose/insulin ratio. The changes in lipids appeared unre-
lated to either marker.
Influence of the obesity subgroup on changes in metabolites
The degree of obesity (Ob group compared with Mob
group) appeared to have little influence on the absolute
changes in the metabolites assessed. The Ob group treated
with 2550 mg metformin showed a mean decline in the
circulating androstenedione concentration of 3.7 ng/ml,
compared with only 1.6 ng/ml in the Ob group treated with
1500 mg metformin. These differences were not significantly
different (P  0.07), and data for the Mob group (decline of
2.1 ng/ml for the 1500-mg group and 1.8 ng/ml for the
2550-mg group) revealed smaller nonsignificant differences.
Most other metabolites showed no difference between the
obesity categories, with the possible exception of IGF-I. The Ob
group showed a mean decrease in circulating IGF-I of 25 ng/ml,
whereas the Mob group showed a mean increase of 12.7 ng/ml.
This difference was statistically significant (P  0.02).
TABLE 3. Correlation evaluations (Spearman’s test where
distributions were non-Gaussian) of the changes in parameters






r2 P r2 P
Androstenedione 0.05 0.07 0.07 0.028
Total cholesterol 0.03 0.151 0.00 0.659
LDL-C 0.00 0.54 0.04 0.13
Leptin 0.37 0.0001 0.15 0.001
TABLE 2. Mean concentrations of analytes at start of treatment [with SD] and the average changes (8 months to T0) during treatment
with metformin in the two dose groups of patients (Ob and Mob patients combined) treated with 1500 or 2550 mg/d
1500 mg/d 2550 mg/d
Dose effect (p)
T0 8m–T0 P T0 8m–T0 P
Fasting insulin (mU/liter) 17.1 [9.9] 1.0 0.746 16.4 [9.3] 1.9 0.043 0.23
Glucose (mM/liter) 5.07 [0.46] 0.09 0.468 4.93 [0.48] 0.13 0.181 0.73
Glucose/insulin ratio 0.38 [0.21] 0.01 0.640 0.37 [0.14] 0.06 0.026 0.16
HOMA-IR 3.96 [2.8] 0.24 0.711 3.73 [1.9] 0.47 0.050 0.29
IGF-I (ng/ml) 187 [98] 1.0 0.856 197.0 [79] 13.9 0.373 0.42
Androstenedione (ng/ml) 11.2 [4.0] 1.7 0.009 11.4 [4.9] 2.5 0.0001 0.36
Testosterone (nmol/liter) 5.2 [2.1] 0.2 0.59 5.4 [3.2] 0.3 0.067 0.25
SHBG 29.9 [18.5] 1.9 0.201 28.5 [9.1] 1.2 0.049 0.85
Free androgen index 10.3 [6.1] 1.3 0.19 11.2 [7.8] 0.5 0.640 0.09
LH (IU/liter) 11.07 [5.8] 1.64 0.605 10.3 [6.0] 0.8 0.305 0.75
DHEAS (g/liter) 5.86 [2.6] 0.67 0.023 6.81 [2.7] 0.47 0.133 0.67
Triglycerides (mmol/liter) 1.59 [0.9] 0.05 0.75 1.86 [1.0] 0.14 0.41 0.57
Total cholesterol (mmol/liter) 5.13 [0.92] 0.29 0.0007 4.99 [0.83] 0.27 0.004 0.76
HDL-C (mmol/liter) 1.10 [0.29] 0.05 0.070 0.97 [0.26] 0.0 0.73 0.83
LDL-C (mmol/liter) 3.30 [0.75] 0.32 0.0001 3.12 [0.85] 0.23 0.004 0.36
Leptin (ng/ml) 69.1 [21.8] 11.8 0.0001 66.3 [28.7] 15.3 0.0001 0.43
CRP 6.89 [5.6] 1.49 0.098 6.54 [7.4] 0.8 0.503 0.65
Values are shown for pretreatment (T0) and the difference after 8 months. The statistical evaluation within groups represents repeated
measures ANOVA assessment for values at T0 and 4 and 8 months. The dose effect is a comparison of the changes between the dose groups.
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Discussion
To our knowledge, this is the first systematic, randomized
study of the effects of different doses of metformin in obese
women with PCOS. The data reveal that women with PCOS
respond to metformin in a manner related to dose and pos-
sibly also body mass, but to only a limited degree. The dose
effect was revealed by the observation that changes in mark-
ers of insulin sensitivity were significant only in the higher
dose group. It was also shown that the degree of weight
reduction in the Ob group was dose related, whereas no such
relationship was determined in the Mob group. Profiles sug-
gesting dose effects on circulating androstenedione concen-
trations were not statistically significant. None of the other
metabolites showed sensitivity to the metformin dose.
The observations confirm that a significant weight reduc-
tion is to be expected with protracted metformin treatment,
but they do not support the concept that the degree of obesity
is influential. This contrasts with the subgroup analysis pre-
viously reported suggesting that Mob patients may be re-
fractory to the treatment benefits (9). Notwithstanding this,
ovarian function appeared to show general improvement in
all subgroups. It is interesting to record that although mea-
sures of insulin resistance changed only in the high dose
group, some markers of cardiovascular risk showed appar-
ent improvements with both metformin doses and both BMI
groups.
The recent Cochrane Library review and its summary (6)
concluded that metformin treatment of women with PCOS
was effective in increasing ovulation rates and suppressing
androstenedione in women with PCOS, but it could not
confirm effects on weight reduction. Many of the studies
quoted in the review included relatively small numbers and
were of generally short duration, and most of the primary
end points were related to ovarian function and fertility. All
these characteristics may reduce the validity of the conclu-
sions with respect to the nonfertility end points. This con-
clusion also contrasts with the findings of the diabetes pre-
vention study (7), with large numbers of individuals (not
PCOS patients) in whom weight loss was consistent and long
lasting. The study reported here was designed to address
weight loss during metformin treatment among PCOS pa-
tients given standard weight-reducing advice, and it shows
convincing evidence supporting a pharmacological effect.
Moreover, although we did not include a placebo group, the
continued weight reduction beyond 4 months in all groups
is notable and differs from the pattern seen with lifestyle
changes, which might have occurred as a study effect.
The effects of metformin on lipid profiles and markers or risk
factors for vascular disease were generally beneficial, but com-
plex. Total cholesterol showed a general decrease, mainly
through a decrease in LDL-C, and there was a trend toward
increased HDL-C. None of these changes in lipid profiles cor-
related with changes in weight or the glucose/insulin ratio. The
absence of an effect on circulating CRP levels also contrasts with
previous studies using relatively low metformin doses, but in
less obese patients (11). It should be restated that most of these
patients remained severely obese.
Additional examination of the relative importance of
weight loss or change in insulin sensitivity revealed little
clear information, except that weight change correlated
strongly with circulating leptin, whereas androstenedione
appeared to be influenced more by the change in insulin
sensitivity.
The changes in lipid profiles showed no dose differential
in either BMI category. It is perhaps not surprising that there
was no consistent change in total triglycerides, because a
large series of women with PCOS, treated with three doses
of troglitazone similarly showed no change in circulating
triglycerides (10), and furthermore, only nonsignificant
trends for a reduction of LDL-C and an increase in HDL-C
were recorded. The review (6) of studies using metformin for
variable durations revealed consistent changes only in
LDL-C. This was in accord with the observations presented
above, along with beneficial changes in total cholesterol.
It is acknowledged that the absence of a placebo group of
patients limits the validity of observations of weight changes,
but a previous study in our unit with placebo in similar
patients given identical advice showed a modest, but sig-
nificant, weight increase over 16 wk (8).
Although relative insulin resistance and its compensa-
tory hyperinsulinemia or insulin hypersecretion are
thought to underpin the etiology of PCOS, the origins of
the ovarian disorder (excessive primordial, primary, and
small antral follicular development) may be established at
birth (16). Correspondingly, a cure at this level is unlikely
until a means of influencing the rate of initial follicle
recruitment and survival to the antral stage can be eluci-
dated. However, the effects of increasing body mass and
hyperinsulinism appear to have a profound impact on
ovarian function and fertility in women with PCOS, and
metformin appears to be defining a role for itself in this
specific area. This study appears to suggest that the doses
used hitherto in Ob and Mob women with PCOS may be
suboptimal, because more consistent effects appear to be
obtained with the higher doses.
It is likely that most of the immediate symptoms of PCOS
will continue to be treated using a symptom-specific ap-
proach, but the role of oral antihyperglycemic medications in
the treatment of these disorders remains to be determined.
With the exception of fertility issues, the principle symptoms
for considering treatment generally require protracted treat-
ment, often in conjunction with other medications.
Optimal doses of metformin in these circumstances have
not been elucidated, but the indication from this study is that
more obvious benefit, subsequent to changes in hormones,
lipids, and weight, may be obtained with doses higher than
those previously explored, particularly in patients with ex-
cessive body mass. However, specific evidence underwriting
this statement is not strong, and additional explorations will
be required.
We conclude that weight loss is a feature of protracted met-
formin therapy in women with PCOS, with greater weight
reduction potentially achievable with higher doses of met-
formin. Future studies should examine whether higher met-
formin doses yield greater clinical benefit, although this exam-
ination indicates that large numbers of patients will be required
to show convincing differences in many parameters.
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